| Literature DB >> 36092382 |
Abdulrahman Altheaby1,2, Kenana Owaidah3, Aljowharah Alotaibi3, Rahaf Salem3, Rihaf Algain3, Areij Alotaibi3, Ahmad Alnasrullah3, Mohammed F Shaheen1,2,4, Mohammed Tawhari2,3,4, Mohamad Abdulgadir1.
Abstract
Background The supply-demand mismatch between organ donor and patient waiting for transplant has led to the growth of transplant tourism. This type of transplant is considered unethical and illegal, as it is usually performed in poor environments and carries a higher risk of infectious, vascular, and immunological complications. Methods In this single-centered retrospective cohort study, we compared patients who underwent transplant tourism to patients who were transplanted locally and followed up in our hospital from January 2015 to December 2018. Result A total of 254 local transplants and 60 patients from the transplant tourism group were included. Transplant tourism recipients were younger otherwise both groups were similar in gender, body mass index, diabetes, and hypertension. Recipients in the transplant tourism group had a significantly higher rate of delayed graft function (18.3% vs. 6.3%, p 0.005), acute rejection (40% vs. 7.9%, p < 0.001), and higher posttransplant infection in general. With more urological complications and higher graft failure at 3-years' follow-up (11.7% vs. 0.8%, p < 0.001). Conclusion Transplant tourism is associated with a higher risk of infection and poor graft outcomes. Extra efforts are required to cut down transplant tourism by educating patients about its clinical risk and ethical considerations. In addition, measures to increase the number of deceased donor pool to provide a better alternative options for patients are essential. Avicenna Journal of Medicine. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: commercial transplant; graft survival; kidney transplantation; posttransplant complications; transplant tourism
Year: 2022 PMID: 36092382 PMCID: PMC9458345 DOI: 10.1055/s-0042-1750715
Source DB: PubMed Journal: Avicenna J Med ISSN: 2231-0770
Baseline characteristics
| Characteristic | Total | Tourism | Local | |
|---|---|---|---|---|
|
| 314 | 60 | 254 | |
| Age | 45.2 ± 15.0 | 40.6 ± 12.4 | 46.3 ± 15.3 | 0.003 |
| Gender | ||||
| Female | 129 | 20 | 109 | 0.192 |
| 41.10% | 33.30% | 42.90% | ||
| Male | 185 | 40 | 145 | |
| 58.90% | 66.70% | 57.10% | ||
| BMI | 27.2 ± 5.3 | 27.5 ± 5.1 | 27.2 ± 5.4 | 0.694 |
| Smoking | ||||
| Never | 269 | 47 | 222 | 0.182 |
| 85.70% | 78.30% | 87.40% | ||
| Smoker | 38 | 11 | 27 | |
| 12.10% | 18.30% | 10.60% | ||
| Ex-smoker | 7 | 2 | 5 | |
| 2.20% | 3.30% | 2.00% | ||
| DM | 81 | 9 | 72 | 0.034 |
| 25.90% | 15.00% | 28.50% | ||
| HTN | 247 | 45 | 202 | 0.484 |
| 78.70% | 75.00% | 79.50% | ||
| CAD | 33 | 4 | 29 | 0.354 |
| 10.50% | 6.70% | 11.40% | ||
| Cause of KF | ||||
| Unknown | 111 | 25 | 86 | 0.292 |
| 35.40% | 41.70% | 33.90% | ||
| GN | 61 | 12 | 49 | |
| 19.40% | 20.00% | 19.30% | ||
| DM | 73 | 10 | 63 | |
| 23.20% | 16.70% | 24.80% | ||
| HTN | 43 | 5 | 38 | |
| 13.70% | 8.30% | 15.00% | ||
| Urological | 19 | 6 | 13 | |
| 6.10% | 10.00% | 5.10% | ||
| Cystic | 7 | 2 | 5 | |
| 2.20% | 3.30% | 2.00% | ||
| Duration of HD | 2.2 ± 2.2 | 2.1 ± 1.7 | 2.3 ± 2.3 | 0.639 |
| Graft type | ||||
| Living | 246 | 55 | 191 | < 0.001 |
| 80.10% | 98.20% | 76.10% | ||
| Deceased | 61 | 1 | 60 | |
| 19.90% | 1.80% | 23.90% | ||
| Previous Tx | 14 | 1 | 13 | 0.321 |
| 4.50% | 1.70% | 5.10% | ||
| Surgical details | 253 | 3 | 250 | < 0.001 |
| 80.80% | 5.00% | 98.80% | ||
| Donor data | 254 | 1 | 253 | < 0.001 |
| 81.20% | 1.70% | 100.00% | ||
| Discharge summary | 266 | 13 | 253 | < 0.001 |
| 85.30% | 22.00% | 100.00% | ||
| Induction | ||||
| ATG | 149 | 15 | 134 | < 0.001 |
| 48.10% | 25.00% | 53.60% | ||
| Basilixmab | 127 | 11 | 116 | |
| 41.00% | 18.30% | 46.40% | ||
| Unknown | 34 | 34 | 0 | |
| 11.00% | 56.70% | 0.00% | ||
| Maintenance therapy | ||||
| Prednisolone | 100% | 100% | 100% | |
| Mycophenolate | 309 | 55 | 254 | < 0.001 |
| 98.40% | 91.70% | 100.00% | ||
| Tacrolimus | 309 | 55 | 254 | 0.006 |
| 99.00% | 94.80% | 100.00% | ||
| Cyclosporine | 8 | 5 | 3 | 0.007 |
| 2.60% | 8.60% | 1.20% | ||
Abbreviations: ATG, anti-thymocyte globulin; BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; GN, glomerulonephritis; HD, hemodialysis; HTN, hypertension; KF, kidney failure.
Graft and patient outcomes
|
Characteristic
| Total | Tourism | Local | |
|---|---|---|---|---|
| DGF | 27 | 11 | 16 | 0.005 |
| 8.60% | 18.30% | 6.30% | ||
| 1st year rejection | 44 | 24 | 20 | < 0.001 |
| 14.00% | 40.00% | 7.90% | ||
| Creatinine | ||||
| 1 wk | 136.9 + 118.1 | 198.0 ± 149.4 | 122.4 ± 104.7 | < 0.001 |
| 1 mo | 107.1 ± 44.5 | 134.9 ± 56.6 | 100.5 ± 38.5 | < 0.001 |
| 6 mo | 102.1 ± 41.5 | 131.9 ± 59.9 | 95.0 ± 32.1 | < 0.001 |
| 12 mo | 99.6 ± 53.3 | 131.9 ± 90.1 | 91.9 ± 36.2 | 0.001 |
| Graft failure | ||||
| During 1st year | 3 | 2 | 1 | 0.096 |
| 1.00% | 3.30% | 0.40% | ||
| Three years | 9 | 7 | 2 | < 0.001 |
| 2.90% | 11.70% | 0.80% | ||
| Mortality | ||||
| During 1st year | 0 | 0 | 0 | |
| 0% | 0% | 0% | ||
| Three years | 1 | 1 | 0 | 0.193 |
| 0.30% | 1.70% | 0.00% | ||
Abbreviation: DGF, delayed graft function.
Posttransplant complications
|
Characteristic
| Total | Tourism | Local | |
|---|---|---|---|---|
| Wound infection | 15 | 10 | 5 | < 0.001 |
| 4.80% | 16.70% | 2.00% | ||
| Wound dehiscence | 4 | 3 | 1 | 0.023 |
| 1.30% | 5.00% | 0.40% | ||
| Collection | 34 | 5 | 29 | 0.645 |
| 10.80% | 8.30% | 11.40% | ||
| Vascular complication | 4 | 1 | 3 | 1 |
| 1.30% | 1.70% | 1.20% | ||
| Urinary leak | 6 | 2 | 4 | 0.6 |
| 1.90% | 3.30% | 1.60% | ||
| UTI | 113 | 34 | 79 | < 0.001 |
| 36.00% | 56.70% | 31.10% | ||
| NODAT | 15 | 1 | 14 | 0.319 |
| 4.80% | 1.70% | 5.50% | ||
| Hepatitis | 4 | 2 | 2 | 0.167 |
| 1.30% | 3.30% | 0.80% | ||
| Bacteremia | 12 | 3 | 9 | 0.706 |
| 3.80% | 5.00% | 3.50% | ||
| Fungal | 0 | 0 | 0 | |
| 0% | 0% | 0% | ||
| CMV viremia | 177 | 38 | 139 | 0.249 |
| 56.40% | 63.30% | 54.70% | ||
| BK viremia | 57 | 16 | 41 | 0.064 |
| 18.20% | 26.70% | 16.10% | ||
| Nephrectomy | 1 | 1 | 0 | 0.191 |
| 0.30% | 1.70% | 0.00% |
Abbreviations: CMV, cytomegalovirus; NODAT, new-onset diabetes after transplantation; UTI, urinary tract infection.